HYMPAVZI® Receives Expanded Indication from FDA
HYMPAVZI® Receives Expanded Indication from FDA
HYMPAVZI® (marstacimab-hncq) is a laboratory-engineered monoclonal antibody that targets an anticoagulant protein known as tissue factor pathway inhibitor. It is administered subcutaneously once a week using a pen-like device.